Organic Active Ingredients TRIZ Cases

NADH coenzyme supplementation facilitates phenylalanine metabolism through alternative pathways, reducing reliance on expensive low-phenylalanine diets.

A PTEN-45aa oligopeptide suppresses glioma cell growth and penetrates tumor tissues.

Aldehyde derivatized glycosaminoglycans join biologically active molecules through nucleophilic addition to form bioconjugates.

Specific 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene compounds improve blood-brain barrier penetration while minimizing off-target side effects.

Modified catecholamine derivatives overcome low oral bioavailability and first-pass metabolism to deliver sustained dopaminergic activity.

Alpha-deuteration extends the half-life of N,N-dimethyltryptamine, eliminating toxic buildup risks in poor metabolizers.

Genetic engineering bacteria secrete diacetylchitobiose deacetylase using a yncM signal peptide.

Identifying loss-of-function mutations in CDKN1A and RB1 genes enables precise selection of cisplatin-based therapies to improve treatment effectiveness.

Replacing synthetic immunostimulators with Aureobasidium sp. beta-glucan resolves the trade-off between reliable immune activation and natural ingredient usage.

Crystallization replaces chromatography to purify aripiprazole lauroxil while sodium bicarbonate substitutes triethylamine in the reaction.

N-substituted arylidenerhodanine compounds stabilize the native tetrameric state of transthyretin to prevent amyloid fibril formation.

Nitrogen atmosphere packaging protects 5-ASA enemas from oxidation, eliminating bowel irritation caused by sulfite stabilizers.

Low-concentration hydrogen peroxide paired with hyaluronic acid resolves the contradiction between disinfection and tissue repair in wound care.

MMP-14 binding proteins inhibit proteolytic activity, reducing tumor growth and metastasis in melanoma and pancreatic cancer.

Controlled crystallization yields stable Marizomib Morphic Form I, resolving the contradiction between manufacturing precision and compound stability.

Dantrolene stabilizes cardiac Ryanodine Receptor 2 to reduce calcium leak and improve defibrillation success.

A single-stranded RNA molecule with specific regions inhibits gene expression through intramolecular folding.

Small molecule compounds inhibit fatty acid synthase activity through selective binding to the thioesterase domain.

Compound 1 targets 5-HT2C receptors to control seizures while avoiding the valvular heart disease risks associated with fenfluramine.

RSC-133 replaces viral vectors to boost reprogramming efficiency and maintain pluripotency without genomic integration risks.

A whey protein isolate and Tween 80 composite emulsifier stabilizes ginsenoside Rg3 and CK nano-emulsions against storage degradation.

A pyridophenanthroline derivative inhibits topoisomerases I and II simultaneously to suppress tumor growth at nanomolar concentrations.

Valine stimulates interferon production to inhibit avian influenza virus proliferation, reducing inflammatory injury and improving survival rates.

Periodic low-dose vitamin B12 supplementation prevents deficiency while minimizing cancer risks associated with continuous high-dose regimens.

An enzymatically resistant polypeptide reduces blood glucose and lipid levels, addressing side effects from conventional diabetes treatments.

Heterocycle compounds inhibit Axl and Mer kinases via specific molecular structures, reducing side effects from off-target activity.

Segmented manufacturing separates excipient compression from probiotic addition, limiting viability loss to 7% compared to 70% in direct methods.

Replacing complex platelet function tests with genetic analysis improves thrombotic risk prediction accuracy and reproducibility.

Direct triplet-triplet energy transfer from a photosensitizer to a BODIPY prodrug enables efficient drug release at 625 nm, avoiding high-power upconversion.

Apyrase depletes extracellular nucleotides alongside P2Y12 inhibition, reducing infarct size while maintaining low bleeding risks.

Pyrrolo[2,3-d]pyrimidinone compounds inhibit cyclin-dependent kinase 2 activity through specific spiro-cyclopropane structural modifications.

Stabilized solid microparticles in a dual-excipient matrix provide sustained therapeutic levels, resolving compliance issues from lengthy oral dosing regimens.

An erodible polymer matrix controls trimetazidine release, reducing peak niacin concentrations that cause flushing while maintaining therapeutic efficacy.

Proteomic blood markers enable patient stratification and treatment monitoring by correlating peripheral protein levels with tissue status.

Glucosylceramide synthase inhibitors target upregulated enzyme activity to suppress proliferation of human papillomavirus-infected cells.

Scorpion venom-derived peptides bind selectively to tumor markers to induce apoptosis, eliminating healthy cell damage from conventional chemotherapy.

Selective laser sintering converts poorly soluble drugs into stable amorphous forms using electromagnetic energy-absorbing excipients.

Bis-triazole triarylpyridines overcome chemoresistance by inducing lysosomal membrane permeabilization to trigger non-apoptotic cell death.

A pharmaceutical composition combining S-Adenosyl-methionine, adaptogenic plant extracts, and vitamins to slow cellular aging.

Peptide compounds inhibit the HCV NS3 protease to overcome limited sustained efficacy of existing interferon therapies.

Replaces chromatography with chiral salt formation and extraction, achieving high optical purity while reducing process complexity.

ACE2 inhibitors mediate viral entry blockage by competing with spike proteins for receptor sites, reducing coronavirus replication.

Purifying benzyl benzoate via antioxidant treatment suppresses fulvestrant sulfone generation during formulation.

Administering alovudine and zidovudine at 1:100 to 1:350 molar ratios mitigates mitochondrial DNA depletion and haematologic toxicity.

Sodium benzoate co-crystals improve bioavailability by selecting co-formers like sorbic acid, reducing development time.

CD99 inhibitors selectively bind CD99 antigens on cancer cells, resolving the contradiction between treatment specificity and intracellular delivery efficiency.

Ruxolitinib blocks the IL-11-Jak/Stat3 pathway driven by stromal Lkb1 loss, reducing tumor burden where COX-2 inhibitors fail.

Formula I compounds inhibit CDK9 kinase activity through specific structural features.

Compositions raise intracellular glutathione levels to reduce HIV viral load despite viral mutation resistance.

Substituted triazolo[4,3-a]pyrazines improve safety and CNS penetrability for treating schizophrenia.

Selective inhibitors of the Na,K-ATPase alpha4 isoform reduce sperm motility, providing a safe and reversible male contraceptive method.

ABC294640 inhibits sphingosine kinase-2 to reduce viral load and respiratory issues while minimizing resistance risks.

Polymorphic Compound I forms resolve manufacturing availability gaps while maintaining precise X-ray diffraction characterization for quality control.

miR-34a-5p agonists and miR-96-5p antagonists regulate oncogenic targets to address high mortality rates in African American prostate cancer patients.

Fiber prebiotics reduce bacterial respiratory activity and stabilize the anaerobic gut environment, preventing antibiotic-induced dysbiosis.

Preventive ferroportin inhibitors block intestinal iron transport, avoiding toxic chelating agents used for post-onset treatment.

Enzymes selectively cleave sn-1 or sn-2 porphyrin-phospholipid regioisomers, resolving acyl migration byproducts that complicate purification.

Alkali metal fumarate improves adhesive layer cohesiveness, resolving insufficient cohesive force and deteriorated emedastine-release characteristics.

Modified purine compounds block CD73-mediated adenosine production, resolving inadequate immunosuppression inhibition in current anticancer treatments.

Oxidizing sugarcane bagasse alpha-cellulose yields spherical carboxy cellulose nanoparticles with high carboxy content.

Triaryldimethylpiperazine polymorph forms B, F, P, J, and O enhance opioid receptor action to address depression through specific delta-receptor targeting.

Cationic lipid particles encapsulate siRNA to deliver therapeutic nucleic acids to liver cells, protecting them from nuclease digestion in plasma.

A wound relief composition stabilizes hypoxia-inducible factor 1-alpha to promote angiogenesis and tissue regeneration.

Anti-properdin antibodies bind properdin to block C5 interaction, preventing alternative complement pathway activation while sparing the classical pathway.

An A/T-rich selectable marker gene prevents epigenetic silencing to sustain elevated transgene levels over time.

Dual protease inhibition by heteroarylcarboxylic acid esters overcomes hypoglycemia risks from conventional diabetes medications.

A nilotinib butanedisulphonate dosage form enhances oral bioavailability through specific microparticle formulation.

Pyridine-substituted Formula I compounds inhibit PRMT5 to reactivate E2F1 apoptotic pathways and control abnormal cell growth in cancer.

High-purity eicosapentaenoic acid ethyl ester addresses ineffective prior therapies by significantly lowering triglyceride levels in resistant patients.

Sequential acetylation, oximation, and hydrolysis steps resolve the contradiction between pharmaceutical purity standards and production efficiency.

Phthalide compounds act as allosteric modulators to decrease oxygen affinity in hemoglobin-based blood substitutes.

A pyrimidodiazepine derivative binds specifically to DNAJC3 and PDIA3 proteins to inhibit tau aggregation.

A coated tablet core uses spray-granulated mannitol and cross-linked croscarmellose sodium to achieve rapid disintegration.

Pyrimidinone carboxamide compounds inhibit endothelial lipase activity, reducing plasma HDL cholesterol and apolipoprotein A-I levels.

Antisense nucleotides suppress Ninjurin 1 protein in macrophages, lowering iNOS expression and NO generation to treat rheumatic arthritis.

Dual inhibition of LSD1 and PLK1 overcomes resistance in altered tumors.

GPR39 antagonists address inadequate hypertension treatments by lowering blood pressure and improving microvascular function.

Beta-nicotinamide mononucleotide acts as an active ingredient to inhibit melanin production in oral formulations.

A bis-linker with a 2,3-diaminosuccinyl group enables site-directed conjugation of cytotoxic drugs to antibody thiols.

Modifying diazepine structures achieves superior P2X4 antagonist activity while avoiding hERG channel inhibition for safe oral administration.

Novel heterocyclic compounds induce apoptosis in cancer cells through p53-independent pathways.

Spiro-oxindole compounds resolve poor cell permeability in peptide-based inhibitors by enhancing bioavailability and sensitizing cancer cells.

CL168 sterol derivative inhibits tumor angiogenesis, preserving normal cells while destroying cancerous tissue.

Novel quinoline compounds with specific structural modifications demonstrate enhanced selectivity and affinity for the serotonin 5-HT6 receptor.

Disulfide linkers enable targeted leptomycin release via glutathione reduction, resolving cytotoxic potency versus systemic toxicity trade-offs.

CDK4/6 inhibitors block clonal hematopoiesis mutation expansion during chemotherapy, reducing myeloid neoplasm risk.

mGlu2/3 negative allosteric modulators treat intellectual disabilities by correcting excessive metabotropic glutamate receptor activation.

Optimized rare ginsenoside ratios overcome pre-systemic metabolism limits to improve cognitive performance.

Segmented vaginal ring maintains hormone release efficacy while eliminating daily compliance issues through replaceable drug cores.

Substituted tyrosine residues in the HMGB1 polypeptide enhance NK cell activation and cytokine release control to reduce toxicity risks.

Controlled particle size distributions in aqueous suspensions reduce injection pain and tissue irritation while maintaining clinical efficacy.

N-benzyl-N-methyldecan-1-amine derivatives inhibit p38 MAP kinase and JNK pathways to treat inflammatory diseases.